ALX Oncology Advances Trials for Evorpacept and ALX2004
No dose-limiting toxicities have been observed to date in ALX Oncology’s first-in-human study of its EGFR-targeted ADC ALX2004, which...
ACTG Launches iPACE-HIV Study on Frailty Intervention
ACTG has opened enrollment for A5426 (IPACE-HIV), a Phase 2, double-blind, randomized study testing the senolytic combination of dasatinib...
Regenera Device May Transform Breast Reconstruction After Trial
Topline data: In a 94-patient pivotal trial in lumpectomy patients receiving adjuvant therapy, Tensive’s REGENERA bioresorbable scaffold met its...
Krystal Biotech Gives Update on Phase 1 Cystic Fibrosis Trial
No efficacy or safety data have been disclosed yet. Krystal Biotech will present an interim look at the highest-dose...
Pulmocide Terminates Phase 3 Opera-T Study of Opelconazole
Interim data from Opera-T showed a numerically lower Day 84 favorable response rate and a numerically higher mortality rate...
Ycanth Phase 3 Trial for Common Warts Doses First Patient
In Phase 2 (COVE-1), YCANTH (VP-102) achieved complete clearance of all treatable common warts at Day 84 in 51%...
Monte Rosa Presents New Interim MRT-8102 Phase 1 Results
Monte Rosa Therapeutics will present interim Phase 1 results for MRT-8102, a NEK7-directed molecular glue degrader, including data from...
Pridcor Long COVID Study Hits FDA & Publication Milestones
An observational case series published in Frontiers in Immunology reports sustained, patient-reported improvements in core Long COVID symptoms—fatigue, dysautonomia,...
New Hope in Trial for Difficult-to-Treat Pediatric Cancers
Two complete metabolic responses in relapsed/refractory metastatic Ewing sarcoma and one complete response in relapsed/refractory metastatic neuroblastoma headline the...
Ernexa’s Promising Cancer Trial Advances with FDA Success
Ernexa Therapeutics has completed a Pre-IND meeting with FDA and is targeting an IND submission to support a first-in-human...